ArticleNature2026
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chromatin accessibility in leukemia: mapping and the limits of reprogramming.Signal transduction and targeted therapy · 2026Article
- Mechanisms of Hematopoietic Stem Cell Aging and Emerging Rejuvenation Strategies.Stem cell reviews and reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
Yotaro OchiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ochi.yotaro.24v@kyoto-u.jp.ORCID http://orcid.org/0000-0001-8472-6164
Markus Liew-LittorinDivision of Hematology, Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID http://orcid.org/0009-0007-5271-1321
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sofia BengtzenCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Benedicte PiaugerDepartment of Hematology, Linköping University Hospital, Linköping, Sweden.
Stefan DenebergCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Martin JäderstenCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Vladimir LazarevicDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0002-1782-4423
Jörg CammengaDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Anna RobeliusDepartment of Medical Sciences, Hematology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-8853-1863
Lovisa WennströmDepartment of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden.ORCID http://orcid.org/0009-0002-7300-5438
Emma ÖlanderDepartment of Hematology, Sundsvall Hospital, Sundsvall, Sweden.
Senji KasaharaDepartment of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.ORCID http://orcid.org/0000-0002-0472-6680
Nobuhiro KanemuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.ORCID http://orcid.org/0000-0001-8449-9918
Nobuo SezakiDepartment of Hematology, Chugoku Central Hospital, Hiroshima, Japan.
Maki SakuradaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Makoto IwasakiDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-7564-157X
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
Yasunori UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University, Nishinomiya, Japan.ORCID http://orcid.org/0000-0002-8537-2422
Tom ErkersScience for Life Laboratory and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-2754-6287
Nona StruyfScience for Life Laboratory and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-6975-0753
Yu WatanabeDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0009-0001-5957-440X
Masanori MotomuraDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masahiro M NakagawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6420-2555
Ryunosuke SaikiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-6984-7187
Hidehito FukushimaDivision of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koji OkazakiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Suguru MorimotoDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akinori YodaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Rurika OkudaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-7124-4171
Shintaro KomatsuDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Guoxiang XieCenter for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0009-0003-4240-3625
Albin ÖsterroosDepartment of Medical Sciences, Hematology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0001-8749-7299
Ayana KonDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Lanying ZhaoDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6144-5845
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Satoru MiyanoDepartment of Integrated Analytics, M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1753-6616
Kotoe KatayamaLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3966-1231
Seiya ImotoLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shuichi MatsudaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-0802-1255
Akifumi Takaori-KondoDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-7678-4284
Hiroyuki AburataniGenome Science & Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Hiroshi I SuzukiDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4682-5086
Olli KallioniemiScience for Life Laboratory and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Gunnar JuliussonDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Martin HöglundDepartment of Medical Sciences, Hematology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-2468-0226
Sören Lehmann *Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. soren.lehmann@ki.se.ORCID http://orcid.org/0009-0009-3243-3947
Seishi Ogawa *Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. sogawa-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-7778-5374
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML
Indexed as
ChromatinEpigenesis, GeneticGenetic HeterogeneityLeukemia, Myeloid, AcuteCohort StudiesDNA MethylationEpigenomicsGene Expression Regulation, LeukemicGene Regulatory NetworksHistonesHumansMultiomicsMutationReproducibility of ResultsSingle-Cell AnalysisSuper EnhancersChromatinHistones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.